Navigation Links
Infinata’s BioPharm Insight™ Achieves Record Growth in 2012

Norwood, MA (PRWEB) February 04, 2013

Infinata’s BioPharm Insight™ capped another year of global expansion in 2012. BioPharm Insight offers subscribers the unique combination of comprehensive market analytics, a database of key industry contacts and proprietary forward-looking intelligence uncovered by an independent team of investigative journalists.

Ruth McHenry, Managing Director of Infinata, said, “BioPharm Insight continues its aggressive growth to meet the needs of industry professionals. Every day we work closely with our customers to understand and solve the challenges they face. I am so proud to say that in 2012 we met and exceeded all targeted areas of growth.”

New Features & Functionalities

New User Interface – BioPharm Insight’s completely redesigned user interface (UI) features a customizable homepage, easier navigation, and interactive charts and graphs. These enhancements allow subscribers to filter data and intelligence to fit their needs, allowing them to identify business opportunities as soon as they arise.

Increased Scope of Data – In addition to a new UI, BioPharm Insight continued to improve the scope of data provided to subscribers with the addition of:

  •     SEC filings
  •     NIH grant data
  •     Medicaid data
  •     EudraCT studies (BioPharm Clinical™)
  •     Expected Catalysts Calendar – by compiling study start and end dates, patent expirations and commercial launches by forecasts, BioPharm Insight provides the most comprehensive calendar of upcoming catalysts.

Analytics – Last year BioPharm Insight added the following analytics to further improve subscribers’ ability to find and use data quickly and efficiently:

  •     CRO activity trends and relationships between sponsors and studies
  •     A Funding Analytics Tab to provide an overview of the venture financing and grant funding markets
  •     Enhanced Epidemiology Intelligence Module - with a single click users can generate custom and detailed reports on indications

BioPharm Clinical, Infinata’s exclusive all-in-one clinical operations support solution, also offered significant additions in 2012:

  •     New Study Advisor™ Timeline and Enrollment Forecasting Tool – Users of BioPharm Clinical enter pertinent protocol information such as indication, inclusion/exclusion criteria, geographic requirements and patient demographics to plan studies more effectively, mitigate risk and reduce costs and delays. Learn more.
  •     +Precision™ Patient Pool Demographic Data Add-on – Clinical operations teams can focus on specific geographic areas with high prevalence and find individual investigators with available patients to meet enrollment targets. Learn more.

Biopharma Industry Data and Trend Reports

Every day BioPharm Insight’s investigative journalists interview subject matter experts, attend scientific and industry/investor conferences and analyze clinical data to keep subscribers up to date on material situations. With a daily stream of original forward-looking intelligence, editorial analysts create data and trend reports to help customers make the most informed decisions in healthcare. In 2012, BioPharm Insight’s editorial analysts released the following data and trend reports to subscribers:

  •     Quarterly Licensing Activity and M&A League Tables – These quarterly reports provided research and insight needed to evaluate market opportunities, market values and trends as well as competitive strategies.
  •     Licensing League Table – This quarterly report provided information on the legal advisors to biotech and pharma licensing agreements.
  •     Catalyst Monitor – This monthly report tracked and analyzed the most material events in the sector for each upcoming month including FDA approvals, Advisory Committee meetings and expected key clinical results.
  •     Global CRO Reports – These reports, covering the US, EMEA and APAC regions, identified key business opportunities in the CRO/CMO sector including enrollment updates and companies that sought or hired a CRO.
  •     Indication Trend Reports – These reports included Obesity, Multiple Sclerosis, Acute Myeloid Leukemia, COPD, Multiple Myeloma, Alzheimer’s disease, Prostate Cancer, HCV, Sarcoma, Melanoma, Pancreatic Cancer, Diabetes, Colorectal Cancer and Breast Cancer.
  •     Pre- and Postconference Reports – Reports covered ASH, AASLD, ACR, AAIC, ADA, ASCO and ACC.

Additional trend reports published last year covered Biosimilars, Sequencing, Distribution, Orphan Drugs and China Healthcare: Licensing & Financing.

Biopharma Industry Education

BioPharm Insight journalists, analysts and executives shared market metrics and intelligence at top biopharma events worldwide. Kimberly Ha, global editor of BioPharm Insight, hosted an expert panel at OneMedForum SF and the Prix Galien USA Forum. Ying Huang, bureau editor for China healthcare, was chosen as the sole media source for the PR Newswire Asia’s Roundtable.

BioPharm Insight also hosted educational webinars featuring discussions with subject matter experts on trends and challenges the industry will face in the next few years. Topics covered included new regulations for pain medications, lipid drug development and global investing trends.

To learn how BioPharm Insight can help you find new business opportunities, start your free trial today. Gain access to all the data, analytics and intelligence mentioned in this news release.

About BioPharm Insight
BioPharm Insight is the definitive guide to the global biopharma community. BioPharm Insight provides subscribers with an information edge by combining the most comprehensive real-time database of companies, drugs, contacts, M&A and licensing deals, forecasts and clinical trial data with proprietary forward-looking intelligence uncovered by an independent team of investigative journalists months or even years before it breaks in mainstream media. To learn more, visit

About Infinata, Inc.
Infinata provides personalized technology solutions to turn information into insight. Services include a comprehensive BioPharm Solutions Suite, unique Wealth Prospecting tools and innovative Custom Data Services. Infinata is a part of Mergermarket, a Financial Times Group company and a division of Pearson plc. To learn more, visit

Read the full story at

Source: PRWeb
Copyright©2012 Vocus, Inc.
All rights reserved

Related biology technology :

1. Infinata's BioPharm Clinical™ to Present Session on Improving Investigator Selection at CHI’s Summit for Clinical Operations (SCOPE) on February 6 in Miami, FL
2. Sutro Biopharma Appoints Edward C. Albini as Chief Financial Officer
3. Array BioPharma To Report Financial Results For The Second Quarter Of Fiscal 2013 On February 4, 2013
4. BioPharm Systems to Host Webinar on an Add-On Solution for Oracle Clinical
5. BioPharm Systems to Host Webinar on Self-service Account Management for Oracle Clinical, Remote Data Capture, and Thesaurus Management System
6. Array BioPharma Provides Updates On Clinical Data At The 2012 American Society Of Hematology Meeting
7. TransCelerate BioPharma Inc. Appoints Dalvir Gill as Chief Executive Officer
8. Array BioPharma Announces Exercise And Closing Of Underwriters Over-Allotment Option
9. Gallus BioPharmaceuticals Announces Appointment of Senior Baxter Executive as Chief Commercial Officer
10. PDL BioPharma to Present at the Lazard Capital Markets 9th Annual Healthcare Conference
11. Keryx Biopharmaceuticals, Inc. Announces Third Quarter 2012 Financial Results
Post Your Comments:
(Date:11/24/2015)... , Nov. 24, 2015 /PRNewswire/ - Aeterna Zentaris Inc. ... IIROC on behalf of the Toronto Stock Exchange, confirms ... there are no corporate developments that would cause the ... --> --> About Aeterna Zentaris ... . --> Aeterna Zentaris is a specialty ...
(Date:11/24/2015)... ... November 24, 2015 , ... The Academy of Model Aeronautics (AMA), ... MultiGP, also known as Multirotor Grand Prix, to represent the First–Person View (FPV) racing ... AMA members have embraced this type of racing and several new model aviation pilots ...
(Date:11/24/2015)... 24, 2015 /PRNewswire/ - Aeterna Zentaris Inc. (NASDAQ: ... the remaining 11,000 post-share consolidation (or 1,100,000 pre-share ... "Series B Warrants") subject to the previously disclosed ... 23, 2015, which will result in the issuance ... to the issuance of such shares, there will ...
(Date:11/24/2015)... ... November 24, 2015 , ... Creation Technologies would ... named to Deloitte's 2015 Technology Fast 500 list of the fastest growing companies ... FDA-cleared, Class II medical device that speeds up orthodontic tooth movement by as ...
Breaking Biology Technology:
(Date:10/26/2015)... ALTO, Calif. and LAS VEGAS ... Nok Nok Labs , an innovator in modern ... Alliance , today announced the launch of its latest ... first unified platform enabling organizations to use standards-based authentication ... The Nok Nok S3 Authentication Suite is ideal for ...
(Date:10/23/2015)... Research and Markets ( ) has announced the ... 2015-2019" report to their offering. ... recognition biometrics market to grow at a CAGR of ... --> The report, Global Voice Recognition Biometrics ... market analysis with inputs from industry experts. The report ...
(Date:10/22/2015)... Oct. 22, 2015  Aware, Inc. (NASDAQ: AWRE ), a ... for its third quarter ended September 30, 2015.  ... of 2015 was $4.0 million, a decrease of 33% compared to ... the third quarter of 2015 was $2.2 million, or $0.10 per ... share, in the same period a year ago.  ...
Breaking Biology News(10 mins):